首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1117313篇
  免费   75755篇
  国内免费   1540篇
耳鼻咽喉   15357篇
儿科学   35992篇
妇产科学   29750篇
基础医学   159498篇
口腔科学   30117篇
临床医学   99575篇
内科学   212688篇
皮肤病学   25209篇
神经病学   86634篇
特种医学   43975篇
外国民族医学   201篇
外科学   166977篇
综合类   22053篇
现状与发展   1篇
一般理论   315篇
预防医学   79879篇
眼科学   25114篇
药学   88903篇
  7篇
中国医学   2887篇
肿瘤学   69476篇
  2021年   9520篇
  2019年   9399篇
  2018年   13196篇
  2017年   10152篇
  2016年   11495篇
  2015年   12795篇
  2014年   17149篇
  2013年   24637篇
  2012年   34424篇
  2011年   36143篇
  2010年   20912篇
  2009年   19531篇
  2008年   32681篇
  2007年   34760篇
  2006年   35276篇
  2005年   33440篇
  2004年   31873篇
  2003年   30435篇
  2002年   29149篇
  2001年   60212篇
  2000年   61615篇
  1999年   51124篇
  1998年   12762篇
  1997年   11246篇
  1996年   11215篇
  1995年   10489篇
  1994年   9461篇
  1993年   8965篇
  1992年   37857篇
  1991年   36337篇
  1990年   35799篇
  1989年   34341篇
  1988年   30914篇
  1987年   30020篇
  1986年   28254篇
  1985年   26483篇
  1984年   19231篇
  1983年   16156篇
  1982年   8852篇
  1979年   17046篇
  1978年   11414篇
  1977年   10249篇
  1976年   8846篇
  1975年   10077篇
  1974年   11654篇
  1973年   11281篇
  1972年   10756篇
  1971年   10095篇
  1970年   9252篇
  1969年   8942篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
102.
103.

Background

The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.

Methods

Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.

Results

Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.

Conclusions

No safety concerns arose, supporting the favorable benefit-risk profile of RZV.  相似文献   
104.
105.
The Impella 5.0, a percutaneously inserted left ventricular assist device, has been used to support patients who have severe heart failure or who are undergoing high-risk percutaneous coronary intervention. We report our surgical placement of the Impella 5.0, through a graft sewn to the aorta, to unload the left ventricle of a 59-year-old man who was undergoing venoarterial extracorporeal membrane oxygenation for postcardiotomy shock. The patient underwent successful placement of a long-term left ventricular assist device before his discharge from the hospital. The versatility of the Impella 5.0 is exemplified in this patient who was successfully bridged to long-term support.  相似文献   
106.
107.
108.
Capillary malformation–arteriovenous malformation syndrome (CM‐AVM) is an autosomal dominant disorder caused by RASA1 mutations. The prevalence and phenotypic spectrum are unknown. Evaluation of patients with multiple CMs is challenging because associated AVMs can be life threatening. The objective of this study was to describe the clinical characteristics of children presenting with features of CM‐AVM to an academic pediatric dermatology practice. After institutional review board approval was received, a retrospective chart review was performed of patients presenting between 2009 and 2012 with features of CM‐AVM. We report nine cases. Presenting symptoms ranged from extensive vascular stains and cardiac failure to CMs noted incidentally during routine skin examination. All demonstrated multiple CMs, two had Parkes Weber syndrome, and two had multiple infantile hemangiomas. Seven patients had family histories of multiple CMs; three had family histories of large, atypical CMs. Six had personal or family histories of AVMs. Genetic evaluation was recommended for all and was pursued by six families; four RASA1 mutations were identified, including one de novo. Consultations with neurology, cardiology, and orthopedics were recommended. Most patients (89%) have not required treatment to date. CM‐AVM is an underrecognized condition with a wide clinical spectrum that often presents in childhood. Further evaluation may be indicated in patients with multiple CMs. This study is limited by its small and retrospective nature.  相似文献   
109.
110.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号